Search NLS News

For six months starting in January 2023 Sweden will hold the Presidency of the Council of the European Union. It is much more than an honorary role, encompassing an opportunity for Sweden to both set new guidelines and see to the implementation of important existing policies. The guiding document for Sweden’s Presidency is the Programme […]

Contract development and manufacturing organizations (CDMOs) are emerging as global key players within the pharmaceutical industry, and their Nordic presence and offering will give the region both resilience and a global competitive edge.

Healthcare stock indices enjoyed a decade-long growth-phase until and including 2017. IPOs within the sector, at arguably far too steep valuations, continued riding on this growth phase, peaking somewhat later in 2020-2021. This phase culminated with a growing number of disappointments between 2020-1H 2022, driven first by gene therapies, then oncology and in neurodegenerative diseases. […]

The startup company has completed a heavily oversubscribed fundraise. The new funds will be used initially to expand the company’s clinical trial program for its Dermalyser AI-driven support tool in Sweden and other key European markets, as well as finalize CE marking and commercialization, states the company. In addition, the company is starting to work towards […]

An international team of researchers have combined ideas from biology, computer science and mathematics to explain why evolution seems to favor symmetry. We spoke with Iain Johnston, a professor at the University of Bergen, and one of the authors behind the article Symmetry and simplicity spontaneously emerge from the algorithmic nature of evolution, published in […]

Modus Therapeutics has submitted a patent application claiming the use of sevuparin, its lead asset, for the treatment of kidney disease. The patent application is based on novel preclinical work that was undertaken in an established kidney disease animal model during an academic collaboration project. A granted patent would provide patent protection until at least […]

Ultimovacs has announced the completed recruitment of 118 patients with pleural mesothelioma in the NIPU trial. NIPU is a randomized, multi-center phase II trial initiated and sponsored by Oslo University Hospital with support from Bristol-Myers Squibb and Ultimovacs. UV1 is being evaluated in combination with the checkpoint inhibitors ipilimumab and nivolumab as second-line treatment for patients with malignant pleural mesothelioma. The ipilimumab and […]

The U.S. Food and Drug Administration has granted the designation for the company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA. In December 2022, Evaxion received FDA approval to proceed with its Phase 2b clinical trial, where EVX-01 is given in combination with KEYTRUDA to patients with metastatic melanoma. On January 17, 2023, Evaxion furthermore […]

The company has raised an additional 10.6 million SEK to accelerate commercialization of its SiPore health and food supplement portfolio. “In the current climate, the rapid completion and oversubscription of this new fund raise is a sign of confidence in both SiPor’s huge potential and our commercialization strategy. In addition to our core prediabetes market, we […]

The new science city in Reykjavik is set to attract growing companies, foreign investors and even more talent. Despite being one of the world’s smallest capitals, Reykjavik has an innovative and creative atmosphere, not least within life sciences. The life science industry includes biotech, pharma, genetics, and medical devices, and it is a growing sector […]